<DOC>
	<DOCNO>NCT02389283</DOCNO>
	<brief_summary>Rheumatoid arthritis ( RA ) chronic inflammatory disease characterize intra peri-articular synovial inflammation . Synovitis damage articular cartilage , bone , joint capsule , tendon ligament lead consequential functional joint deterioration . The main goal RA treatment achieve disease remission . The treatment RA consist synthetic biologic disease modify drug ( DMARDs ) , second one select low disease remission achieve first one . Therapeutic response monitoring RA closely manage . It classically base clinical exploration laboratory test . During last decade , resolution improvement musculoskeletal ultrasound ( MSUS ) image lead gradual incorporation technique evaluation monitoring patient RA , mainly due good capacity detect synovitis clinical exploration . Ultrasound image highly available , non-invasive , reproducible , affordable well accepted patient . Ultrasound doppler mode detect pathological synovial flow , reflect synovial inflammation demonstrate sensitivity change multiple longitudinal study . Sonographic evaluation patient RA include detection synovitis B Doppler mode joint accessible ultrasound . There high variability literature regard number joint evaluated appropriate monitoring RA patient . The validity monitor therapeutic response long stand RA demonstrate three reduce joint count , include 12 , 7 6 joint . However , short evolution RA , sensitivity change reduce ultrasound evaluation never study</brief_summary>
	<brief_title>Reduced Ultrasound Counts Rheumatoid Arthritis</brief_title>
	<detailed_description>Primary objective • To evaluate sensitivity change Doppler Ultrasound evaluation 12 , 7 6 joint count RA patient 6 month le 5 year evolution , initiate effective treatment disease accord indication ( biologic DMARD monotherapy combine methotrexate ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patients gender , ≥ 18 year age Patients diagnose RA ( accord ACR 2010 criterion ) 6 month le 5 year active evolution DAS28 &gt; 3.2 SDAI &gt; 11 , start treatment biologic DMARD first time , accord product 's summary product characteristic ( SPC ) . Patients grant write informed consent collection review data . Patients already participate clinical trial/s moment participation study . Patients rheumatic disease RA</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Rheumatoid arthritis</keyword>
	<keyword>ultrasound joint count</keyword>
</DOC>